Related guidance:

Chronic kidney disease: assessment and management NICE guideline (August 2021, updated November 2021)

Dapagliflozin for treating chronic kidney disease Technology appraisal guidance (TA775 March 2022)

Empagliflozin for treating chronic kidney disease Technology appraisal guidance (TA942 December 2023)

For Dapaglifozin and Empaglifozin see NHS Somerset Blood glucose lowering drugs

Cardiovascular disorders: assessing fitness to drive (DVLA March 2016, updated June 2022)

2.1 - Arrhythmias
2.3 - Blood clots
2.4 - Blood pressure conditions
2.6 - Heart Failure
2.7 - Hyperlipidaemia
2.8 - Myocardial ischaemia
2.9 - Oedema
2.10 - Vascular disease